Register entry
- Registered sites
- 0
- Active NDC listings
- 10
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
1010 active NDC listings: 10 drug for further processing. By marketing category: DRUG FOR FURTHER PROCESSING 10.
| Dosage form | NDCs |
|---|---|
| tablet, film coated | 10 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| ipr pharmaceuticals, inc | 10 |
Catalogue
Marketed products
10| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | dapagliflozin | tablet, film coated | 54921-620DRUG FOR FURTHER PROCESSING |
| - | dapagliflozin | tablet, film coated | 54921-621DRUG FOR FURTHER PROCESSING |
| - | rosuvastatin calcium | tablet, film coated | 54921-751DRUG FOR FURTHER PROCESSING |
| - | rosuvastatin calcium | tablet, film coated | 54921-752DRUG FOR FURTHER PROCESSING |
| - | rosuvastatin calcium | tablet, film coated | 54921-754DRUG FOR FURTHER PROCESSING |
| - | rosuvastatin calcium | tablet, film coated | 54921-755DRUG FOR FURTHER PROCESSING |
| - | rosuvastatin calcium | tablet, film coated | 54921-756DRUG FOR FURTHER PROCESSING |
| - | rosuvastatin calcium | tablet, film coated | 54921-757DRUG FOR FURTHER PROCESSING |
| - | rosuvastatin calcium | tablet, film coated | 54921-758DRUG FOR FURTHER PROCESSING |
| - | rosuvastatin calcium | tablet, film coated | 54921-759DRUG FOR FURTHER PROCESSING |
Compare
Other companies listing rosuvastatin calcium
- Zhejiang Yongtai Pharmaceutical Co., Ltd.2 sites · 11 NDC
Enquiry
Common questions
- Is IPR Pharmaceuticals, Inc FDA approved?
- IPR Pharmaceuticals, Inc holds no registered establishment of its own; 10 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does IPR Pharmaceuticals, Inc make?
- 10 products are listed under IPR Pharmaceuticals, Inc in the openFDA NDC Directory, most often as tablet, film coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.